Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Dentsply Sirona enters five-year partnership agreement with Smile Train » 07:39
09/24/21
09/24
07:39
09/24/21
07:39
XRAY

Dentsply Sirona

$59.63 /

+0.03 (+0.05%)

Dentsply Sirona is…

Dentsply Sirona is launching this partnership with Smile Train to improve oral health globally and to build a brighter, more sustainable future for children and families affected by cleft worldwide. We are going beyond traditional financial and equipment donations. The Dentsply Sirona and Smile Train partnership will advance the future of cleft care by: Supporting global treatment standards and best practices for digitized cleft care; Leveraging digital technologies to make treatments more efficient and convenient for children; Providing high quality equipment to develop state-of-the-art centers for cleft treatment; Making our entire online catalog of clinical education courses available to all Smile Train oral health professionals; and Offering financial support for cleft surgeries. The company is focused on making sure the benefits of our Smile Train partnership have a lasting impact. Therefore, in addition to funding life-changing cleft surgeries and providing free dental equipment, the collaboration focuses on global, oral healthcare training initiatives to equip people in local communities with the skills needed to provide treatment and raise the standard of care to the highest level through Clinical Education and the use of cutting-edge technologies in the long term. Additionally, the partnership includes the development of an International Smile Train Scholars program, which will support in-person and virtual training and learning opportunities for Smile Train dental partners. A group of 16 scholars are attending DS World 2021, participating in clinical education sessions and growing their professional networks.

ShowHide Related Items >><<
XRAY Dentsply Sirona
$59.63 /

+0.03 (+0.05%)

XRAY Dentsply Sirona
$59.63 /

+0.03 (+0.05%)

08/10/21 Goldman Sachs
SmileDirectClub price target lowered to $4 from $7 at Goldman Sachs
08/09/21 H.C. Wainwright
Dentsply Sirona price target lowered to $66 from $72 at H.C. Wainwright
08/06/21 Barrington
Dentsply Sirona price target raised to $79 from $77 at Barrington
08/06/21 Piper Sandler
Dentsply Sirona weakness a buying opportunity, says Piper Sandler
XRAY Dentsply Sirona
$59.63 /

+0.03 (+0.05%)

XRAY Dentsply Sirona
$59.63 /

+0.03 (+0.05%)

Recommendations
Tandem Diabetes price target raised to $135 from $123 at SVB Leerink » 07:29
09/24/21
09/24
07:29
09/24/21
07:29
TNDM

TNDM

/

+

SVB Leerink analyst…

SVB Leerink analyst Danielle Antalffy raised the firm's price target on Tandem Diabetes to $135 from $123 and keeps a Market Perform rating on the shares. While Antalffy believes the insulin pump market will continue to grow strong double-digits, and Tandem Diabetes will also continue to grow, the analyst is somewhat skeptical that the company can continue to drive the extent of sales upside over the mid to long-term that it has seen over the last several years, she tells investors in a research note.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

08/05/21 SVB Leerink
Tandem Diabetes price target raised to $123 from $102 at SVB Leerink
08/05/21 Craig-Hallum
Tandem Diabetes price target raised to $153 from $140 at Craig-Hallum
08/05/21 Wells Fargo
Tandem Diabetes price target raised to $121 from $112 at Wells Fargo
08/05/21 Oppenheimer
Tandem Diabetes price target raised to $140 from $135 at Oppenheimer
TNDM TNDM
/

+

Thursday
Hot Stocks
Harpoon Therapeutics CFO buys 10.3K shares of common stock » 08:14
09/23/21
09/23
08:14
09/23/21
08:14
HARP

Harpoon Therapeutics

$8.13 /

-0.25 (-2.98%)

In a regulatory filing,…

In a regulatory filing, Harpoon Therapeutics disclosed that its CFO Georgia Erbez bought 10.3K shares of common stock on September 22nd in a total transaction size of $83.4K, boosting her stake by about 12%. Shares of Harpoon Therapeutics are up about 4% in pre-market trading at $8.42.

ShowHide Related Items >><<
HARP Harpoon Therapeutics
$8.13 /

-0.25 (-2.98%)

HARP Harpoon Therapeutics
$8.13 /

-0.25 (-2.98%)

08/06/21 Piper Sandler
Harpoon Therapeutics price target lowered to $30 from $35 at Piper Sandler
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
06/08/21
Fly Intel: Top five analyst downgrades
06/08/21 Citi
Harpoon Therapeutics downgraded to Neutral from Buy at Citi
HARP Harpoon Therapeutics
$8.13 /

-0.25 (-2.98%)

  • 07
    Jan
Hot Stocks
Dentsply Sirona announces new sustainability strategy » 07:41
09/23/21
09/23
07:41
09/23/21
07:41
XRAY

Dentsply Sirona

$59.60 /

+0.37 (+0.62%)

Dentsply Sirona announced…

Dentsply Sirona announced its updated sustainability strategy, the release of its inaugural sustainability report, and new sustainability hub on its website. Dentsply Sirona's disclosure is aligned with the guidelines from the Sustainability Accounting Standards Board and the Task Force for Climate-related Financial Disclosures. "Dentsply Sirona's sustainability strategy focuses on three strategic pillars: 'Healthy Planet,' which strives to mitigate the environmental impact of our operations; 'Healthy Smiles,' which focuses on improving oral health quality and access globally, supporting our customers and fostering a healthy company culture; and, 'Healthy Business,' which ensures our business is built via responsible and transparent practices and the effective integration of sustainability principles across all aspects of our business," the company said. 2020 sustainability highlights and the next milestones: "Healthy Planet" highlights: established a robust baseline for Scopes 1 and 2 greenhouse gas emissions, and implemented a range of on-site emissions reduction initiatives; set out to reduce Scopes 1 and 2 GHG Emissions Reduction more than or equal 15% by 2025, and to achieve net zero carbon emissions by 2050; 6% YOY decrease in total waste per measure of net sales, and set out to reduce total waste more or equal than 15% by 2025; and established a goal to reduce water withdrawal for manufacturing/warehouse operations by more or equal to 15% by 2025. "Healthy Smiles" highlights: trained more than 1M dental professionals in 2020; nearly 7,300 Clinical Education and training courses conducted in 80 countries; set goal to achieve 25 million smiles by 2025; working to achieve gender parity and gender pay parity by 2025; and more than $10M provided in cash and in-kind donations to philanthropic and community initiatives. "Healthy Business" highlights: 50% of Board members are gender and/or ethnically diverse, with average tenure of 5 years; 60% of Board committees chaired by women; and 91% of Board is independent.

ShowHide Related Items >><<
XRAY Dentsply Sirona
$59.60 /

+0.37 (+0.62%)

XRAY Dentsply Sirona
$59.60 /

+0.37 (+0.62%)

08/10/21 Goldman Sachs
SmileDirectClub price target lowered to $4 from $7 at Goldman Sachs
08/09/21 H.C. Wainwright
Dentsply Sirona price target lowered to $66 from $72 at H.C. Wainwright
08/06/21 Barrington
Dentsply Sirona price target raised to $79 from $77 at Barrington
08/06/21 Piper Sandler
Dentsply Sirona weakness a buying opportunity, says Piper Sandler
XRAY Dentsply Sirona
$59.60 /

+0.37 (+0.62%)

XRAY Dentsply Sirona
$59.60 /

+0.37 (+0.62%)

Conference/Events
SVB Leerink to hold a virtual event » 04:55
09/23/21
09/23
04:55
09/23/21
04:55
AVRO

Avrobio

$6.12 /

-0.1 (-1.61%)

, CRNX

Crinetics

$20.88 /

-0.01 (-0.05%)

, INSM

Insmed

$26.66 /

+0.03 (+0.11%)

, MREO

Mereo BioPharma

$2.53 /

+ (+0.00%)

, ORTX

Orchard Therapeutics

$2.41 /

-0.065 (-2.63%)

, RPHM

Reneo Pharmaceuticals

$8.09 /

+0.36 (+4.66%)

, SPRB

Spruce Biosciences

$6.40 /

-0.11 (-1.69%)

, TALS

Talaris Therapeutics

$14.68 /

+0.37 (+2.59%)

Neuromuscular, Rare…

Neuromuscular, Rare Diseases & Genetic Medicines Virtual Event to be held on September 22-23.

ShowHide Related Items >><<
TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

SPRB Spruce Biosciences
$6.40 /

-0.11 (-1.69%)

RPHM Reneo Pharmaceuticals
$8.09 /

+0.36 (+4.66%)

ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

MREO Mereo BioPharma
$2.53 /

+ (+0.00%)

INSM Insmed
$26.66 /

+0.03 (+0.11%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

AVRO Avrobio
$6.12 /

-0.1 (-1.61%)

AVRO Avrobio
$6.12 /

-0.1 (-1.61%)

06/14/21 BTIG
Avrobio initiated with a Buy at BTIG
05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
06/18/21 JPMorgan
Crinetics upgraded to Overweight from Neutral at JPMorgan
05/03/21 JonesTrading
Crinetics initiated with a Buy at JonesTrading
11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
INSM Insmed
$26.66 /

+0.03 (+0.11%)

04/26/21 Credit Suisse
Insmed assumed with an Outperform at Credit Suisse
02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
MREO Mereo BioPharma
$2.53 /

+ (+0.00%)

05/05/21
Fly Intel: Top five analyst initiations
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/05/21 Needham
Mereo BioPharma initiated with a Buy at Needham
ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

08/18/21 JPMorgan
Orchard Therapeutics downgraded to Neutral from Overweight at JPMorgan
07/02/21 Wedbush
Pharming collaboration offers upside for Orchard Therapeutics, says Wedbush
06/30/21 JPMorgan
Orchard Therapeutics price target lowered to $14 from $15 at JPMorgan
06/30/21 Cantor Fitzgerald
Orchard Therapeutics price target lowered to $12 from $17 at Cantor Fitzgerald
RPHM Reneo Pharmaceuticals
$8.09 /

+0.36 (+4.66%)

05/20/21 Piper Sandler
Reneo valuation presents 'ideal opportunity,' says Piper Sandler
05/04/21 SVB Leerink
SVB Leerink bullish on Reneo Pharmaceuticals, initiates with an Outperform
05/04/21 SVB Leerink
Reneo Pharmaceuticals initiated with an Outperform at SVB Leerink
05/04/21 Jefferies
Reneo Pharmaceuticals initiated with a Buy at Jefferies
SPRB Spruce Biosciences
$6.40 /

-0.11 (-1.69%)

07/19/21 H.C. Wainwright
Spruce Biosciences initiated with a Buy at H.C. Wainwright
04/26/21 Credit Suisse
Spruce Biosciences assumed with an Outperform at Credit Suisse
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 SVB Leerink
SVB Leerink bullish on Spruce Biosciences, initiates with an Outperform
TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

06/01/21 SVB Leerink
Talaris Therapeutics initiated with an Outperform at SVB Leerink
06/01/21 Evercore ISI
Evercore starts Talaris Therapeutics at Outperform with $35 price target
06/01/21 Evercore ISI
Talaris Therapeutics initiated with an Outperform at Evercore ISI
06/01/21 Guggenheim
Talaris Therapeutics initiated with a Buy at Guggenheim
TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

SPRB Spruce Biosciences
$6.40 /

-0.11 (-1.69%)

ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

INSM Insmed
$26.66 /

+0.03 (+0.11%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

AVRO Avrobio
$6.12 /

-0.1 (-1.61%)

  • 11
    May
  • 07
    May
  • 08
    Apr
  • 09
    Apr
  • 10
    Feb
  • 20
    Nov
  • 09
    Oct
ORTX Orchard Therapeutics
$2.41 /

-0.065 (-2.63%)

TALS Talaris Therapeutics
$14.68 /

+0.37 (+2.59%)

RPHM Reneo Pharmaceuticals
$8.09 /

+0.36 (+4.66%)

INSM Insmed
$26.66 /

+0.03 (+0.11%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

CRNX Crinetics
$20.88 /

-0.01 (-0.05%)

Wednesday
Hot Stocks
Axonics Medtronic provides update on inter partes review proceedings » 18:14
09/22/21
09/22
18:14
09/22/21
18:14
AXNX

Axonics

$69.84 /

+0.56 (+0.81%)

, MDT

Medtronic

$128.90 /

+1 (+0.78%)

Axonics (AXNX) announced…

Axonics (AXNX) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic (MDT) patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review to contest the validity of patents Medtronic has alleged to be infringed by Axonics. In September 2020, the PTAB granted Axonics' request and instituted a review of the six Medtronic patents. On September 13, 2021, the PTAB issued its decision with respect to Patent Nos. 7,774,069; 8,626,314, and 8,036,756. Today, the PTAB issued its decision on the three remaining Medtronic patents Axonics is contesting: Patent Nos. 9,821,112 ('112 patent), 8,457,758 ('758 patent); and 8,738,148 ('148 patent). Either party may appeal the IPR decisions to the Director of the Patent & Trademark Office and to the U.S. Court of Appeals for the Federal Circuit. Axonics expects the stay on legal proceedings in the U.S. District Court in the Central District of California to continue until the appeals process is complete. "First and foremost, it is important to understand that the PTAB rulings as to whether the claims in the Medtronic patents are valid or not do not mean that anyone has 'won' anything. When one party suggests that another party is infringing, the other party often asks the PTAB to determine if the claims in the patents are actually valid. This is what Axonics has done and for Medtronic to claim 'victory' is purely posturing. The fact that the PTAB decided to invalidate several claims in Medtronic's '112 patent is a net positive for Axonics. Moreover, we believe the PTAB's narrow construction of the claims in the '758 patent and '148 patent strengthens our non-infringement argument. Axonics remains confident that it does not infringe any Medtronic patents - valid or invalid - and that we will ultimately prevail on the patent claims asserted against us," said Raymond Cohen, CEO of Axonics.

ShowHide Related Items >><<
MDT Medtronic
$128.90 /

+1 (+0.78%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

08/06/21 Barclays
Axonics price target raised to $79 from $74 at Barclays
08/06/21 Piper Sandler
Axonics price target raised to $78 from $75 at Piper Sandler
07/16/21 Barclays
Axonics recall of Bulkamid is not material, says Barclays
07/12/21
Fly Intel: Top five analyst initiations
MDT Medtronic
$128.90 /

+1 (+0.78%)

09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/27/21 Argus
Medtronic price target raised to $165 from $150 at Argus
08/25/21 Truist
Medtronic price target raised to $148 from $138 at Truist
08/25/21 Credit Suisse
Medtronic price target raised to $146 from $137 at Credit Suisse
MDT Medtronic
$128.90 /

+1 (+0.78%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

  • 12
    May
MDT Medtronic
$128.90 /

+1 (+0.78%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

Initiation
Neurocrine initiated with a Hold at Needham » 16:26
09/22/21
09/22
16:26
09/22/21
16:26
NBIX

Neurocrine

$94.29 /

-1.31 (-1.37%)

Needham analyst Ami Fadia…

Needham analyst Ami Fadia initiated coverage of Neurocrine with a Hold rating. The company has 4 late-stage programs, but the Street is unlikely to give much credit for these as data readouts for most are not likely before 2023, the analyst tells investors in a research note. Faida adds that while Neurocrine will have 7 Phase 2 trials underway by year-end FY21, adding longer-term growth drivers, the stock is unlikely to reflect these until more data becomes available, which is "not likely anytime soon".

ShowHide Related Items >><<
NBIX Neurocrine
$94.29 /

-1.31 (-1.37%)

NBIX Neurocrine
$94.29 /

-1.31 (-1.37%)

08/06/21 Canaccord
Neurocrine downgraded to Hold from Buy at Canaccord
06/29/21 BofA
US 1 List Changes at BofA
05/18/21 Goldman Sachs
Neurocrine assumed with a Neutral at Goldman Sachs
05/10/21 Cantor Fitzgerald
Neurocrine price target lowered to $117 from $128 at Cantor Fitzgerald
NBIX Neurocrine
$94.29 /

-1.31 (-1.37%)

NBIX Neurocrine
$94.29 /

-1.31 (-1.37%)

Initiation
Intra-Cellular initiated with a Buy at Needham » 16:24
09/22/21
09/22
16:24
09/22/21
16:24
ITCI

Intra-Cellular

$37.22 /

+0.01 (+0.03%)

Needham analyst Ami Fadia…

Needham analyst Ami Fadia initiated coverage of Intra-Cellular with a Buy rating and $55 price target. The analyst believes Caplyta's growth is underappreciate and that there is pipeline upside. Fadia anticipates Caplyta will gain approval for bipolar disorder depression at the December 17, 2021 PDUFA and projects sales quickly growing to $435M in 2024 and $775M in 2026.

ShowHide Related Items >><<
ITCI Intra-Cellular
$37.22 /

+0.01 (+0.03%)

ITCI Intra-Cellular
$37.22 /

+0.01 (+0.03%)

09/20/21 Jefferies
Intra-Cellular price target raised to $70 from $55 at Jefferies
12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
12/15/20 BofA
Intra-Cellular initiated with a Buy at BofA
ITCI Intra-Cellular
$37.22 /

+0.01 (+0.03%)

Initiation
Ideaya Biosciences initiated with a Hold at Stifel » 16:16
09/22/21
09/22
16:16
09/22/21
16:16
IDYA

Ideaya Biosciences

$27.10 /

+0.1 (+0.37%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett initiated coverage of Ideaya Biosciences with a Hold rating and $27 price target. The analyst said that while he resonates with the synthetic lethality approach, he worries that clinical data for lead SL program IDE397 will come in below expectations.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$27.10 /

+0.1 (+0.37%)

IDYA Ideaya Biosciences
$27.10 /

+0.1 (+0.37%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
IDYA Ideaya Biosciences
$27.10 /

+0.1 (+0.37%)

  • 08
    Jul
IDYA Ideaya Biosciences
$27.10 /

+0.1 (+0.37%)

Hot Stocks
Icon awarded EUR4M R&D support contract in Ireland » 16:08
09/22/21
09/22
16:08
09/22/21
16:08
ICLR

Icon

$274.62 /

+4.42 (+1.64%)

The Tanaiste and Minister…

The Tanaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD announced htat ICON plc has been awarded EUR4M in R&D support administered by Enterprise Ireland to further enhance its data solutions and decentralised clinical trial technology. The COVID-19 pandemic has accelerated the clinical research industry's move to hybrid and decentralised trials, requiring researchers and regulatory bodies to adapt to the ways participants live their connected and mobile lives. As the most advanced healthcare intelligence and clinical research organisation in the industry, ICON will utilise the funding to further invest in the build-out of its world-class technology and data solutions architecture. The support will promote broad clinical research participation while also delivering real-time access to data, higher levels of security, and improved timelines and reduced costs for customers.

ShowHide Related Items >><<
ICLR Icon
$274.62 /

+4.42 (+1.64%)

ICLR Icon
$274.62 /

+4.42 (+1.64%)

09/14/21 Jefferies
Icon price target raised to $302 from $276 at Jefferies
08/04/21 Credit Suisse
Icon assumed with an Outperform at Credit Suisse
07/26/21 Deutsche Bank
Icon price target raised to $234 from $212 at Deutsche Bank
07/23/21 Citi
Icon upgraded to Buy from Neutral at Citi
ICLR Icon
$274.62 /

+4.42 (+1.64%)

ICLR Icon
$274.62 /

+4.42 (+1.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.